Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of enabling technologies and services for the global pharmaceutical and chemical industries, is pleased to announce the installation of its second Self-Driving Laboratory ("SDL") at Pfizer, as part of the multi-year agreement between the companies. The installation was completed in January 2026.TRANSACTION HIGHLIGHTSThe present SDL ...

Core Viewpoint - The article highlights five dividend stocks that are currently attractive for income-focused investors, particularly in light of overvalued growth stocks. Group 1: PepsiCo - PepsiCo is recommended over Coca-Cola due to its higher forward-looking dividend yield of 3.5% compared to Coke's 2.6% [4] - The company's stock has underperformed due to challenges in its food and snack business, but initiatives like healthier product options are positively impacting its financials [4] Group 2: Pfizer - Pfizer's revenue peaked at over $100 billion in 2022 due to COVID-19 but has since declined as the company focused on pandemic response [5] - The company plans to launch eight new blockbuster drugs by 2030, which could increase annual revenue from around $60 billion to $80 billion [7] - Pfizer's current dividend yield is 6.3%, making it an attractive option for income investors [8] Group 3: Realty Income - Realty Income is a REIT that has consistently paid monthly dividends since 1969 and has raised its per-share payment for over 31 years [10] - The REIT focuses on brick-and-mortar retail, with a high occupancy rate of 98.7%, indicating resilience despite challenges in the retail sector [11] Group 4: Verizon - Verizon offers a forward-looking dividend yield of 5.8% and has increased its quarterly payment for 19 consecutive years [12] - The company's strong customer dependency on mobile services supports its stable income generation [14] Group 5: IBM - IBM has a dividend yield of 2.6% and has raised its payment annually for the past 30 years [15] - A significant portion of IBM's revenue comes from high-margin software and consulting services, with annualized recurring revenue from software subscriptions at $23.6 billion [18]

Core Viewpoint - Pfizer offers a unique combination of scale, stability, and a 6% dividend yield, which is rare among large-cap companies, suggesting a potential investment opportunity [1] Group 1: Financial Performance - Pfizer has steady cash flow, which supports its dividend yield and overall financial health [1] - The company is currently valued modestly, indicating potential for growth and investment upside [1] Group 2: Market Position - As a defensive giant, Pfizer may be positioning itself for a rebound in the market, making it an attractive option for income-focused investors [1] - Analysts suggest that there is upside potential for Pfizer, which could enhance its appeal as a value play [1]

Group 1 - The primary goal of the "High Income DIY Portfolios" service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers seven portfolios designed for income investors, including retirees, featuring three buy-and-hold portfolios, three rotational portfolios, and a conservative NPP strategy portfolio [1] - The portfolios include two high-income portfolios, two dividend growth investing (DGI) portfolios, and a conservative NPP strategy portfolio aimed at low drawdowns and high growth [1] Group 2 - The "High Income DIY Portfolios" service includes a total of 10 model portfolios with varying income targets and risk levels, along with buy and sell alerts and live chat support [2] - The investment approach focuses on dividend-growing stocks with a long-term horizon, aiming for 30% lower drawdowns and 6% current income [2] - The service is managed by a financial writer with 25 years of investment experience, emphasizing strategies for stable, long-term passive income [2]

Core Viewpoint - The article discusses the importance of diversifying investment portfolios beyond the financial sector to include income opportunities from other sectors for a balanced retirement portfolio [1]. Group 1: Investment Strategy - The company emphasizes the need for a diversified stock portfolio that includes various sectors, not just the financial sector [1]. - The author has over 18 years of experience in financial markets, focusing on portfolio management and buy-side institutions [1]. Group 2: Analyst Background - The author is a Fund Manager/Analyst specialized in the financial sector, indicating a strong background in investment analysis [1]. - The article is written by an individual with a beneficial long position in PFE shares, suggesting a vested interest in the stock mentioned [2].

Pharmaceutical giant Pfizer (NYSE: PFE) recently had to drop its internally developed GLP-1 weight loss drug candidate. The unfortunate outcome is that the company has had to watch rivals Novo Nordisk and Eli Lilly build early leads in this fast-growing drug niche. With Pfizer facing patent expirations ahead -- and now this GLP-1 setback -- Wall Street remains downbeat on the stock. But that's a potential opportunity for long-term investors. Where to invest $1,000 right now? Our analyst team just reveale ...

Key Takeaways AstraZeneca posted 8% revenue and 11% core EPS growth in 2025, led by 16 blockbusters.AZN guides mid-to-high single-digit 2026 revenue growth and targets $80B sales by 2030.Pfizer faces COVID declines and a 2026 LOE hit, with sales and EPS seen falling next year.Pfizer (PFE) and AstraZeneca (AZN) are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company revenues. Beyond cancer therapies ...

​Pfizer Inc. (NYSE:PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17, Pfizer Inc. (NYSE:PFE) announced positive results from its key BREAKWATER trial, which is testing BRAFTOVI in combination with cetuximab and FOLFIRI in patients with metastatic colorectal cancer. Management noted that the combination showed significant PFS improvement and better overall survival. Although the overall survival was a secondary descriptive endpoint, without statistics, it showed clinically meaningfu ...

Core Insights - Pfizer is transitioning from a peak revenue era driven by the coronavirus vaccine, which generated over $37 billion in 2022, to a new growth phase through strategic acquisitions and product development [1][2][4]. Group 1: Revenue and Market Position - The demand for coronavirus vaccines has declined, and Pfizer is facing the loss of exclusivity for older blockbuster drugs, impacting its revenue streams [2][4]. - Despite these challenges, Pfizer reported over $10 billion in revenue from recent product launches and acquisitions last year, up from $8.9 billion the previous year [10]. Group 2: Strategic Acquisitions - Pfizer's acquisition of Seagen has provided access to several commercialized drugs, including Padcev for bladder cancer, which has achieved blockbuster status with over $1 billion in annual revenue [6]. - The company has also acquired Metsera, focusing on developing weight loss drug candidates, which is a growing market expected to approach $100 billion by the end of the decade [8][9]. Group 3: Future Growth Potential - Pfizer is focusing on in-house research and development and aims to reinvest $500 million in R&D by the end of the year [10]. - The company is exploring monthly dosing for its weight loss drug candidate, which could differentiate it in a market currently dominated by weekly dosing options [9].

BioNTech sues Moderna for patent infringement over COVID-19 shots | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed Biontech logo in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration [Purchase Licensing Rights, opens new tab]- Companies[BioNTech SE]Follow[Moderna Inc]Follow[Pfizer Inc]FollowFeb 19 (Reuters) - Biopharm ...